Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBK | Q96KB5 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | ATR | Q13535 | 4/20 | 0.46 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.46 |
| ▸ | PAK4 | O96013 | 2/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.44 |
| ▸ | BTK | Q06187 | 8/20 | 0.42 |
| ▸ | TEC | P42680 | 1/20 | 0.42 |
| ▸ | TXK | P42681 | 1/20 | 0.42 |
| ▸ | BMX | P51813 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2019866 | 0.86 | ALDH1A1 (0.50) | ATRATRIP | |
| SCHEMBL2019864 | 0.86 | ALDH1A1 (0.50) | ATRATRIP | |
| SCHEMBL2018105 | 0.82 | JAK3 (0.69) | PBKJAK3DOT1LBTKJAK2 | |
| SCHEMBL1017284 | 0.78 | JAK3 (0.58) | JAK3PAK4DOT1LJAK2HRH4 | |
| SCHEMBL1018334 | 0.77 | TSHR (0.47) | PBKJAK3JAK2HRH4 | |
| SCHEMBL1018704 | 0.76 | JAK3 (0.59) | JAK3PAK4DOT1LJAK2HRH4 | |
| SCHEMBL13392108 | 0.74 | JAK2 (0.57) | JAK3JAK2 | |
| SCHEMBL2022714 | 0.74 | PAK4 (0.57) | JAK3PAK4BTK | |
| SCHEMBL3953793 | 0.71 | DOT1L (0.68) | PBKJAK3DOT1LBTKJAK2 | |
| SCHEMBL3955342 | 0.71 | PBK (0.70) | PBKJAK3DOT1LBTKTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| CN-101679440-A | Pyrrolopyrimidine derivatives as jak3 inhibitors | PALAU PHARMA SA | 2010-03-24 | — | — | CN | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PBK 1013/4885JAK3 1/4885ATR 2658/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | PBK 1013/4885JAK3 1/4885ATR 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.